Claims for Patent: 9,358,270

Summary for Patent: 9,358,270

Title:	Method of treating rhinitis with B-type and C-type natriuretic peptides
Abstract:	The problem to be solved by the present invention is to provide an effective and safe therapeutic preparation for rhinitis, which not only has significant effects on improvement in rhinitis, in particular allergic rhinitis, but also is rapid in manifestation of efficacy, fast-acting, and long-lasting, without local side effects. Means for solving the problem is a therapeutic preparation for rhinitis, in particular allergic rhinitis, comprising C-type natriuretic peptide (CNP) or B-type natriuretic peptide (BNP) as the active ingredient.
Inventor(s):	Endo; Kyoko (Sendai, JP)
Assignee:	IGISU Co., Ltd. (Tokyo, JP) Endo; Kyoko (Sendai, JP) Endo; Yori (Sendai, JP)
Application Number:	14/193,017
Patent Claims:	1. A method of treating rhinitis in a subject in need thereof comprising: administering to the subject a therapeutic preparation comprising C-type natriuretic peptide (CNP) or B-type natriuretic peptide (BNP) as the active ingredient, wherein the therapeutic preparation is a nasal drop preparation, and wherein a concentration of the C-type natriuretic peptide (CNP) or the B-type natriuretic peptide (BNP) is 10-500 .mu.g/g in the therapeutic preparation, wherein CNP is selected from the group of consisting of CNP-22 and CNP-53, wherein the sequence of CNP-22 is SEQ ID NO: 1 and the sequence of CNP-53 is SEQ ID NO: 22, wherein BNP is selected from the group of consisting of BNP-26, BNP-32 and BNP-45, and wherein BNP-32 is SEQ ID NO: 2, the sequence of BNP-26 is SEQ ID NO: 23 and the sequence of BNP-45 is SEQ ID NO: 24 or SEQ ID NO: 25. 2. The method of treating rhinitis according to claim 1, wherein the C-type natriuretic peptide (CNP) is CNP-22. 3. The method of treating rhinitis according to claim 1, wherein the B-type natriuretic peptide (BNP) is BNP-32. 4. The method of treating rhinitis according to claim 1, wherein the concentration of the C-type natriuretic peptide (CNP) or the B-type natriuretic peptide (BNP) is 50-200 .mu.g/g in the therapeutic preparation. 5. The method of treating rhinitis according to claim 1, wherein the concentration of the C-type natriuretic peptide (CNP) or the B-type natriuretic peptide (BNP) is 50-100 .mu.g/g in the therapeutic preparation. 6. The method of treating rhinitis according to claim 1, wherein the rhinitis is infectious rhinitis, hypersensitive non-infectious rhinitis, irritant rhinitis, atrophic rhinitis, or specific granulomatous rhinitis. 7. The method of treating rhinitis according to claim 6, wherein the infectious rhinitis is acute rhinitis or chronic rhinitis. 8. The method of treating rhinitis according to claim 6, wherein the hypersensitive non-infectious rhinitis is combined-type rhinitis (hypersensitive nose), rhinorrhea-type rhinitis, congestive-type rhinitis, or dry-type rhinitis. 9. The method of treating rhinitis according to claim 8, wherein the combined-type rhinitis (hypersensitive nose) is allergic rhinitis. 10. The method of treating rhinitis according to claim 1, wherein the allergic rhinitis is allergic rhinitis against at least one allergen selected from the group consisting of house dust, mite, cedar, orchard grass, ragweed, and cat hair. 11. The method of treating rhinitis according to claim 6, wherein the irritant rhinitis is physical irritant-induced rhinitis, chemical irritant-induced rhinitis or radiation-induced rhinitis. 12. The method of treating rhinitis according to claim 1, wherein the rhinitis is atrophic rhinitis or specific granulomatous rhinitis. 13. The method of treating rhinitis according to claim 1, wherein the rhinitis is mixed-type rhinitis, sneezing/rhinorrhea-type rhinitis, or nasal-occlusion-type rhinitis. 14. The method of treating rhinitis according to claim 1, wherein the dosage form is a nasal drop preparation selected from an ointment preparation, a gel preparation, a cream preparation, a lotion preparation, a liquid preparation, a powder preparation or a spray preparation. 15. The method of treating rhinitis according to claim 1, wherein the nasal drop preparation is selected from a gel preparation, a liquid preparation or a spray preparation. 16. The method of treating rhinitis according to claim 1, wherein the rhinitis is rhinitis in a subject suffering from atopic dermatitis. 17. The method of treating rhinitis according to claim 1, wherein the rhinitis is rhinitis with treatment resistance to steroids. 18. The method of treating for rhinitis according to claim 1, wherein the rhinitis is rhinitis in a subject having a difficulty in withdrawal from steroids. 19. The method of treating rhinitis according to claim 1, wherein the rhinitis is rhinitis with treatment resistance to antihistamine drugs.

Details for Patent 9,358,270

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Allermed Laboratories, Inc.	N/A	animal allergens, standardized cat hair	Injection	103473	03/12/1974		2029-08-27